These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24630537)

  • 1. Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial.
    Barillot I; Tavernier E; Peignaux K; Williaume D; Nickers P; Leblanc-Onfroy M; Lerouge D
    Radiother Oncol; 2014 Apr; 111(1):138-43. PubMed ID: 24630537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy.
    Chen CC; Wang L; Lu CH; Lin JC; Jan JS
    J Formos Med Assoc; 2014 Dec; 113(12):949-55. PubMed ID: 24144528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective randomised phase II trial evaluating adjuvant pelvic radiotherapy using either IMRT or 3-Dimensional planning for endometrial cancer.
    Nugent K; Browne D; Dunne M; O Sullivan L; Shannon AM; Sharma D; Bradshaw S; McArdle O; Salib O; Lavan N; Gillham C
    Acta Oncol; 2023 Aug; 62(8):907-914. PubMed ID: 37493622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes using adjuvant pelvic intensity modulated radiation therapy (IMRT) for endometrial carcinoma.
    He S; Gill BS; Heron DE; Kelley JL; Sukumvanich P; Olawaiye AB; Edwards RP; Comerci J; Beriwal S
    Pract Radiat Oncol; 2017; 7(1):19-25. PubMed ID: 27527897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous Integrated Boost Volumetric Modulated Arc Therapy in the Postoperative Treatment of High-Risk to Intermediate-Risk Endometrial Cancer: Results of ADA II Phase 1-2 Trial.
    Macchia G; Cilla S; Deodato F; Ianiro A; Legge F; Marucci M; Cammelli S; Perrone AM; De Iaco P; Gambacorta MA; Autorino R; Valentini V; Morganti AG; Ferrandina G
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):606-13. PubMed ID: 27681755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
    Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
    Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose.
    Kwak YK; Lee SW; Kay CS; Park HH
    PLoS One; 2017; 12(8):e0183339. PubMed ID: 28846718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of adjuvant treatment of endometrial cancer using aperture-based intensity-modulated radiotherapy.
    Bouchard M; Nadeau S; Gingras L; Raymond PE; Beaulieu F; Beaulieu L; Fortin A; Germain I
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1343-50. PubMed ID: 18294780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
    Poorvu PD; Sadow CA; Townamchai K; Damato AL; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1262-8. PubMed ID: 23182395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients.
    Lips IM; Dehnad H; van Gils CH; Boeken Kruger AE; van der Heide UA; van Vulpen M
    Radiat Oncol; 2008 May; 3():15. PubMed ID: 18495016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-tandem high-dose-rate brachytherapy for early-stage medically inoperable endometrial cancer: Initial report on acute toxicity and dosimetric comparison to stereotactic body radiation therapy.
    Kauffmann G; Wu T; Al-Hallaq H; Hasan Y
    Brachytherapy; 2017; 16(1):141-146. PubMed ID: 27866953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of three different approaches of small bowel delineation and acute lower gastrointestinal toxicity in adjuvant pelvic intensity-modulated radiation therapy for endometrial cancer.
    Chi A; Nguyen NP; Xu J; Ji M; Tang J; Jin J; Ong ES; Welsh JS
    Technol Cancer Res Treat; 2012 Aug; 11(4):353-9. PubMed ID: 22475067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
    Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
    Chen MJ; Weltman E; Hanriot RM; Luz FP; Cecílio PJ; da Cruz JC; Moreira FR; Santos AS; Martins LC; Nadalin W
    Radiat Oncol; 2007 Jan; 2():6. PubMed ID: 17224072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Outcomes of a Dose-reduction Trial to Decrease Late Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Sasaki N; Yamazaki H; Shimizu D; Suzuki G; Masui K; Nakamura S; Okabe H; Nishikawa T; Yoshida K
    Anticancer Res; 2018 Jan; 38(1):385-391. PubMed ID: 29277799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.
    Vargo JA; Kim H; Houser CJ; Berhane H; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
    Radiother Oncol; 2014 Oct; 113(1):126-31. PubMed ID: 25241996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.